share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K：外國發行人報告
美股sec公告 ·  06/13 21:53
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, successfully conducted its Annual General Meeting (AGM) on June 13, 2024. During the meeting, all resolutions presented to the shareholders were approved. The company, which focuses on developing innovative products for diseases with unmet medical needs, highlighted its lead development programs, including eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer. Biodexa's proprietary drug delivery technologies aim to improve the bio-delivery and bio-distribution of medicines. The full details of the resolutions passed at the AGM are available on the company's website. The company's headquarters and R&D facility are located in Cardiff, UK.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, successfully conducted its Annual General Meeting (AGM) on June 13, 2024. During the meeting, all resolutions presented to the shareholders were approved. The company, which focuses on developing innovative products for diseases with unmet medical needs, highlighted its lead development programs, including eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer. Biodexa's proprietary drug delivery technologies aim to improve the bio-delivery and bio-distribution of medicines. The full details of the resolutions passed at the AGM are available on the company's website. The company's headquarters and R&D facility are located in Cardiff, UK.
Biodexa藥品公司是一家上市於納斯達克逐筆明細爲BDRX的臨床階段生物製藥公司，於2024年6月13日成功舉行了年度股東大會。在會議期間，所有提交給股東的決議均獲得批准。該公司專注於開發針對醫療領域中未被滿足的疾病的創新藥品，重點推出了其首席開發項目，包括用於家族性腺瘤性息肉病和非肌侵襲性膀胱癌的eRapa，用於1型糖尿病的tolimidone，以及用於罕見/孤兒腦癌的MTX110。Biodexa自有的藥物傳遞技術旨在改善藥物的傳遞與分佈。有關大會通過的所有決議的詳細信息可在公司網站上獲得。該公司總部和研發設施位於英國卡迪夫。
Biodexa藥品公司是一家上市於納斯達克逐筆明細爲BDRX的臨床階段生物製藥公司，於2024年6月13日成功舉行了年度股東大會。在會議期間，所有提交給股東的決議均獲得批准。該公司專注於開發針對醫療領域中未被滿足的疾病的創新藥品，重點推出了其首席開發項目，包括用於家族性腺瘤性息肉病和非肌侵襲性膀胱癌的eRapa，用於1型糖尿病的tolimidone，以及用於罕見/孤兒腦癌的MTX110。Biodexa自有的藥物傳遞技術旨在改善藥物的傳遞與分佈。有關大會通過的所有決議的詳細信息可在公司網站上獲得。該公司總部和研發設施位於英國卡迪夫。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。